We Are CSL

The largest plasma fractionation facility in the Southern Hemisphere, the plant manufactures biotherapies that treat rare and life-threatening conditions including immunodeficiencies, neurological disorders, shock and burns. The facility processes domestic plasma from Australia, New Zealand, Taiwan, Hong Kong and Malaysia donor plasma, in addition to plasma sourced commercially through CSL Plasma. CSL Behring Broadmeadows is also home to a cell-culture biotechnology manufacturing plant that uses biotech processes to grow non-human genetically engineered cells that are purified into therapies for patients.

Marburg is the largest manufacturing site in the CSL network. The core products are coagulation and specialty products for the treatment of patients in 110 countries. The site offers an integrated supply chain including a large and innovative plasma fractionation facility, bulk production, filling and visual inspection, as well as automated packaging. In addition to plasma products, Marburg manufactures recombinant, cell-based products and is an established partner in the CSL network offering contract manufacturing operations (CMO) activities in filling and packaging.

The CSL Behring Kankakee site is the largest manufacturing employer in Kankakee County. Products produced at Kankakee include alpha-1 proteinase inhibitor (to treat patients with alpha-1 deficiency and clinical evidence of emphysema) and albumin (to treat shock, burns and provide fluid replacement), and stable intermediate pastes manufactured into plasma-derived therapies to treat rare and life-threatening conditions, including immunodeficiencies, neurological disorders and bleeding disorders.

The Bern facility develops and manufactures innovative biotherapies derived from human plasma and serving patients across the globe. In the heart of the city of Bern, CSL Behring looks back on a long and successful history in the immunoglobulin market. Continuous innovation combined with the highest demands on quality and the use of cutting-edge technology have made the site a global leader in the field of immunotherapy.

The site in Wuhan is responsible for domestic manufacture of plasma-based therapies. The facility processes plasma sourced in China to manufacture immunoglobulin and albumin therapies for distribution in the domestic market. CSL Behring Wuhan additionally operates five plasma collection centers in Hubei province that source the plasma donations required for the Wuhan site to produce life-saving therapies for Chinese patients.

Acquired in 2019, the Union facility makes the liquid saline and sodium citrate solutions used in plasma collection. The facility plays a key role in the CSL supply chain and supporting the company’s production of life-saving plasma-derived therapies for patients.

The U.K.’s only injectable influenza vaccine manufacturing facility and one of the largest biotechnology sites in Europe.

A center of excellence for the manufacture of enhanced influenza vaccines, utilizing egg-based and adjuvant technology, the Liverpool plant’s bulk manufacturing capability and expanded fill and finish lines enable the efficient production of seasonal influenza vaccines for both northern and southern hemispheres. It also plays an important role in providing pandemic preparedness and response for the U.K. and other countries in Europe.

The world’s largest cell-based influenza vaccine manufacturing facility, and the first and only company to be recognized by the U.S. Government as having a pandemic ready designation.

Purpose-built in partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to combat pandemic threats, the state-of-the-art facility specializes in highly scalable cell-based vaccine technology and produces a proprietary adjuvant, MF59®. Recent expansion works including the addition of new formulation suites and expanded fill and finish capacity, ensure pre-pandemic, pandemic and seasonal influenza vaccines can be efficiently produced and distributed across the USA and beyond.

Australia’s first influenza vaccine manufacturer.

The site continues a long legacy in the manufacture of products of national significance for the Australian Government, including antivenoms and the Q fever vaccine. It also plays a significant role in influenza prevention, producing egg-based seasonal, pre-pandemic and pandemic vaccines for Australia and worldwide. The Parkville facility also plays a key role in the global fight against influenza by developing candidate vaccine viruses for the World Health Organisation in the Asia Pacific region.

Upon opening in 2026, Tullamarine will be the Southern Hemisphere’s premier cell culture influenza vaccine manufacturing and research facility.

CSL Seqirus’ latest facility features best-in-class sustainability paired with innovative production capabilities to tackle global and region-specific public health needs. Products manufactured here will include cell-based seasonal, pre-pandemic and pandemic influenza vaccines, as well as those of national significance to the Australian government. This includes the world’s only Q fever vaccine and antivenom for deadly snakes, spiders and marine creatures.

Founded in 1952 as Laboratorien Hausmann, CSL Vifor’s high-tech manufacturing site in St. Gallen has developed into a highly automated facility for the manufacture of iron-based Active Pharmaceutical Ingredients (API’s). With its consistent production technologies and controlled manufacturing processes, it is also home to CSL Vifor’s nanomedicine research and production.